Postdoctoral Scientist – Cancer Dynamics

Cancer Research UK Manchester Institute; Manchester; On-site; GBP 80,000 - 100,000; Full time

Job summary

A leading cancer research institute in Manchester is seeking a postdoctoral scientist to study cancer initiation and metastasis using cutting-edge genetic engineering technology. The ideal candidate will have a PhD in cancer biology and experience with 3D organoid cultures and genetic engineering. This role offers a unique opportunity to work in a world-class research environment directly linked with clinical treatment centers.

Qualifications

• Ability to independently design and carry out research projects.
• Experience in establishing and maintaining 3D organoid cultures.
• Desirable experience in CRISPR screens and drug screens.

Responsibilities

• Work with cutting-edge technology to understand cancer initiation and metastasis.
• Study targeting recurrent aneuploidies in cancer initiation and metastases.
• Develop novel therapeutic strategies for better cancer treatments.

Skills

PhD in cancer biology or relevant discipline

Experience establishing and maintaining 3D organoid cultures

Genetic engineering and identification of positive clones

Experience with CRISPR screen or drug screen

In vitro co-culture experiments

In vivo xenograft and metastasis models

Education

PhD

Job description

About the role:

We are looking for a postdoctoral scientist to work with a cutting‑edge technology to understand cancer initiation and metastasis in our lab Cancer Dynamics which operates across the Cancer Research UK Manchester Institute and the Francis Crick Institute. The role will be based in Manchester with a visiting scientist status at the Crick taking advantage of both research communities.

You will study the Targeting Recurrent Aneuploidies in Cancer Initiation and Metastases in the laboratory of Prof SamraTurajlić. This multidisciplinary project sits at the intersection of cancer genomics, preclinical modelling, and translational therapeutics.

This is a unique opportunity to work with our special clinical resources and cutting‑edge genetic engineering technology to uncover how aneuploidy drives cancer initiation and progression, and to develop novel therapeutic strategies for better cancer treatments.

BACKGROUND:

Targeting Recurrent Aneuploidies in Cancer Initiation and Metastases: Aneuploidy, characterised by an imbalanced chromosome copy number is a hallmark of cancer1 and increasingly recognised in normal tissues2. Despite its prevalence, the functional consequences of aneuploidy across biological contexts remain poorly characterised due to experimental challenges in generating relevant aneuploidy models.

Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, causing ~150,000 deaths annually. Its initiation is almost universally driven by chromosome 3(p) loss3, while chromosome 9(p) and chromosome 14(q) losses are strongly associated with metastatic progression4. These distinct recurrent aneuploidy patterns in ccRCC evolution makes it an ideal model for investigating how aneuploidies in normal epithelial cells drive tumour initiation and how aneuploidies in tumour cells promote disease progression.

About you:

You should have a PhD in cancer biology or other relevant discipline along with the ability to independently design and carry out research projects. You will have experience of establishing and maintaining 3D organoid cultures and experience of genetic engineering and identification of positive clones. Experience of CRISPR screen or drug screen is desirable as is experience of in vitro co‑culture experiments and with in vivo xenograft and metastasis models.

Why choose Cancer Research UK Manchester Institute?

The Cancer Research UK Manchester Institute, an Institute of The University of Manchester, is a world‑leading centre for excellence in cancer research. The Institute is core funded by Cancer Research UK, the largest independent cancer research organisation in the world. In spring 2023 the Institute moved into the new Paterson Building, a £150 million flagship purpose‑built biomedical research centre directly attached to The Christie NHS Foundation Trust, in South Manchester.

We are partnered with The Christie NHS Foundation Trust, one of the largest cancer treatment centres in Europe. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes.

How to apply?

For further information about the project and to apply for this position please visit our website.

Closing date: Sunday 23 November 2025.